MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/ene.14820

Медицинская библиотека · European journal of neurology · 2021

Clinical characteristics and outcomes of thymoma-associated myasthenia gravis.

Álvarez-Velasco Rodrigo, Gutiérrez-Gutiérrez Gerardo, Trujillo Juan Carlos, Martínez Elisabeth, Segovia Sonia, Arribas-Velasco Marina, Fernández Guillermo, Paradas Carmen, Vélez-Gómez Beatriz, Casasnovas Carlos, Nedkova Velina, Guerrero-Sola Antonio, Ramos-Fransi Alba, Martínez-Piñeiro Alicia, Pardo Julio, Sevilla Teresa, Gómez-Caravaca María Teresa, López de Munain Adolfo, Jericó Ivonne, Pelayo-Negro Ana L, Martín María Asunción, Morgado Yolanda, Mendoza María Dolores, Pérez-Pérez Helena, Rojas-García Ricard, Turon-Sans Janina, Querol Luis, Gallardo Eduard, Illa Isabel, Cortés-Vicente Elena

СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND AND PURPOSE: Prognosis of myasthenia gravis (MG) in patients with thymoma is not well established. Moreover, it is not clear whether thymoma recurrence or unresectable lesions entail a worse prognosis of MG.

METHODS

This multicenter study was based on data from a Spanish neurologist-driven MG registry. All patients were aged >18 years at onset and had anti-acetylcholine receptor antibodies. We compared the clinical data of thymomatous and nonthymomatous patients. Prognosis of patients with recurrent or nonresectable thymomas was assessed.

RESULTS

We included 964 patients from 15 hospitals; 148 (15.4%) had thymoma-associated MG. Median follow-up time was 4.6 years. At onset, thymoma-associated MG patients were younger (52.0 vs. 60.4 years, p < 0.001), had more generalized symptoms (odds ratio [OR]: 3.02, 95% confidence interval [CI]: 1.95-4.68, p < 0.001) and more severe clinical forms according to the Myasthenia Gravis Foundation of America (MGFA) scale (OR: 1.6, 95% CI: 1.15-2.21, p = 0.005). Disease severity based on MGFA postintervention status (MGFA-PIS) was higher in thymomatous patients at 1 year, 5 years, and the end of follow-up. Treatment refractoriness and mortality were also higher (OR: 2.28, 95% CI: 1.43-3.63, p = 0.001; hazard ratio: 2.46, 95% CI: 1.47-4.14, p = 0.001). Myasthenic symptoms worsened in 13 of 27 patients with recurrences, but differences in long-term severity were not significant. Fifteen thymomatous patients had nonresectable thymomas with worse MGFA-PIS and higher mortality at the end of follow-up.

CONCLUSIONS

Thymoma-associated MG patients had more severe myasthenic symptoms and worse prognosis. Thymoma recurrence was frequently associated with transient worsening of MG, but long-term prognosis did not differ from nonrecurrent thymoma. Patients with nonresectable thymoma tended to present severe forms of MG.

Для цитирования: Álvarez-Velasco Rodrigo, Gutiérrez-Gutiérrez Gerardo, Trujillo Juan Carlos, Martínez Elisabeth, Segovia Sonia, Arribas-Velasco Marina, Fernández Guillermo, Paradas Carmen, Vélez-Gómez Beatriz, Casasnovas Carlos, Nedkova Velina, Guerrero-Sola Antonio, Ramos-Fransi Alba, Martínez-Piñeiro Alicia, Pardo Julio, Sevilla Teresa, Gómez-Caravaca María Teresa, López de Munain Adolfo, Jericó Ivonne, Pelayo-Negro Ana L, Martín María Asunción, Morgado Yolanda, Mendoza María Dolores, Pérez-Pérez Helena, Rojas-García Ricard, Turon-Sans Janina, Querol Luis, Gallardo Eduard, Illa Isabel, Cortés-Vicente Elena. Clinical characteristics and outcomes of thymoma-associated myasthenia gravis.. European journal of neurology. 2021. DOI: 10.1111/ene.14820.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.